Antares Pharma, Inc. v. Medac Pharma Inc.
771 F.3d 1354
Fed. Cir.2014Background
- Antares owns U.S. Patent No. 7,776,015 ("the ’015 patent") directed to a needle-assisted jet injector; original claims all included a "jet injection" limitation and prosecution repeatedly distinguished prior art on that basis.
- About 22 months after issuance, Antares obtained a broadening reissue (RE44,846, "the ’846 patent") adding claims 23–37; asserted claims 31, 34, 35, and 37 claim combinations of safety features for injection devices without the "jet" limitation.
- Medac submitted an FDA 505(b)(2) NDA for pre-filled methotrexate syringes; Antares sued and moved for a preliminary injunction alleging § 271(e)(2)(A) artificial infringement by the NDA filing.
- Medac opposed, arguing the asserted reissue claims are invalid under 35 U.S.C. § 251 for failing the "original patent" requirement and for violating the recapture rule (i.e., surrendered subject matter cannot be regained on reissue).
- The district court denied the preliminary injunction, finding Antares unlikely to succeed on the merits because the reissue claims likely violated the recapture rule; Antares appealed.
- The Federal Circuit affirmed on the independent ground that the reissue claims fail the § 251 original-patent requirement because the original specification did not clearly and unequivocally disclose the newly claimed safety-feature combinations apart from the jet-injector invention.
Issues
| Issue | Plaintiff's Argument | Defendant's Argument | Held |
|---|---|---|---|
| Whether reissue claims satisfy § 251’s "original patent" requirement (i.e., reissue must be for the invention disclosed in the original patent) | Antares: specification disclosed "overlooked aspects" and embodiments (e.g., push button) that justify the broader reissue claims | Medac: original specification only disclosed a jet-injector invention; safety features were mentioned only as part of that invention and not expressly disclosed as separate claimed inventions | Held: Reissue claims invalid under § 251 — the specification did not explicitly and unequivocally disclose the newly claimed safety-feature combinations apart from the jet-injector invention. |
| Whether recapture rule precludes the reissue claims (surrendered subject matter cannot be regained) | Antares: recapture rule inapplicable under "overlooked aspects" precedent | Medac: prosecution statements limited claims to jet injectors, so reissue broadening recaptures surrendered subject matter | Court: Did not decide recapture rule on appeal because it affirmed based on § 251 failure. |
| Whether Antares showed likelihood of success to secure a preliminary injunction | Antares: likely to succeed and face irreparable harm absent injunction | Medac: reissue claims likely invalid so Antares cannot show likelihood of success | Held: Antares failed to show likelihood of success because asserted claims invalid under § 251; preliminary injunction properly denied. |
| Whether factual issues require remand on § 251 (given appeal from preliminary injunction) | Antares: factual disputes might exist | Medac: § 251 issue is legal and can be resolved on the record | Held: No remand required — § 251 issue resolved as a matter of law on the present record. |
Key Cases Cited
- U.S. Indus. Chem., Inc. v. Carbide & Carbon Chem. Corp., 315 U.S. 668 (1942) (reissue valid only if original specification fully and clearly discloses the claimed invention; mere suggestion or indication not enough)
- In re Mostafazadeh, 643 F.3d 1353 (Fed. Cir. 2011) (discusses recapture rule and "overlooked aspects" line of cases)
- In re Amos, 953 F.2d 613 (Fed. Cir. 1991) (reissue upheld where the exact embodiment asserted on reissue was expressly disclosed in the original specification)
- Ariad Pharm. v. Eli Lilly & Co., 598 F.3d 1336 (Fed. Cir. 2010) (written-description standard: specification must show inventor "invented what is claimed")
- LifeScan Scotland Ltd. v. Shasta Techs., LLC, 734 F.3d 1361 (Fed. Cir. 2013) (addresses when reissue/original-patent issues can be resolved on the record without remand)